66 completed, 23 recruiting, 23 terminated, 16 active not recruiting. 154 Phase 2, 32 Phase 1, 6 Phase 3.
Follow Nerve Sheath Neoplasms: new trials by email Literature Review of Nerve Sheath Neoplasms trials Research Report on Nerve Sheath Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1) | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 55 | 2027-01-01 | 2026-10-05 |
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 25 | 2027-01-01 | 2026-10-28 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Mirdametinib in Patients With Advanced NF1-mutant Melanoma Mirdametinib - Advanced Unresectable Melanoma, Metastatic Melanoma | Phase 2 | Recruiting | Kevin Kim, MD | 10 | 2025-10-13 | 2025-11-19 |
| Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap Tulavi allay Nerve Cap - Neuroma, Neuropathic Pain | Phase 2 | Recruiting | Massachusetts General Hospital | 20 | 2025-09-20 | 2026-04-17 |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2025-08-27 | 2026-05-29 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| Using CICS-1 and SPM-011 and [18F]FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, [18F]FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 HLX-1502 - Neurofibromatosis Type 1 | Phase 2 | Recruiting | Healx Limited | 25 | 2025-02-10 | 2026-07-29 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children Selumetinib - Plexiform Neurofibromas (PN) | Phase 2 | Not yet recruiting | West China Hospital | 50 | 2025-01-01 | 2025-01-08 |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia Trametinib, Azacitidine, Fludarabine - Leukemia, Juvenile Myelomonocytic, JMML | Phase 1 / Phase 2 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 58 | 2024-10-11 | 2026-09-04 |
Showing 20 of 154. Sign in to see all of them.
Neurofibrosarcoma (57) · Neurofibromatosis 1 (55) · Sarcoma (40) · Leiomyosarcoma (30) · Sarcoma, Synovial (29) · Neurofibroma, Plexiform (28) · Histiocytoma, Malignant Fibrous (25) · Liposarcoma (24) · Neurofibromatosis 2 (24) · Fibrosarcoma (23) · Neuroma, Acoustic (22) · Hemangiosarcoma (21) · Rhabdomyosarcoma (19) · Sarcoma, Alveolar Soft Part (17) · Neurofibromatoses (15)
Neoplasms by Histologic Type (154) · Neoplasms, Nerve Tissue (153) · Neoplasms (152) · Nervous System Diseases (152) · Neurofibroma (131) · Neuromuscular Diseases (123) · Peripheral Nervous System Diseases (121) · Nervous System Neoplasms (120) · Peripheral Nervous System Neoplasms (115) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (90) · Genetic Diseases, Inborn (88) · Neoplastic Syndromes, Hereditary (88) · Neurodegenerative Diseases (86) · Heredodegenerative Disorders, Nervous System (85)
AZD 6244 (17) · Doxorubicin (8) · Imatinib Mesylate (7) · Everolimus (6) · Bevacizumab (5) · Sirolimus (5) · pazopanib (5) · trametinib (5) · Ifosfamide (4) · mirdametinib (4) · Lovastatin (3) · pembrolizumab (3) · Acetylcysteine (2) · Etoposide (2) · Inhalation (2)
National Cancer Institute (NCI) (19) · University of Alabama at Birmingham (10) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Memorial Sloan Kettering Cancer Center (6) · Massachusetts General Hospital (5) · Sarcoma Alliance for Research through Collaboration (5) · Beijing Tiantan Hospital (4) · Novartis Pharmaceuticals (4) · Children's Hospital Medical Center, Cincinnati (3) · Indiana University (3) · NYU Langone Health (3) · Assistance Publique - Hôpitaux de Paris (2) · AstraZeneca (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Massachusetts Eye and Ear Infirmary (2)
United States (105) · China (13) · France (8) · Canada (7) · Germany (7) · Belgium (6) · Netherlands (6) · United Kingdom (6) · Spain (5) · Australia (4) · Denmark (4) · Austria (3) · Poland (3) · Brazil (2) · Japan (2)
Brigitte C Widemann, M.D. (5) · AeRang Kim, MD, PhD (3) · Girish Dhall, MD (3) · Matthias A Karajannis, MD, MS (3) · Scott Plotkin, MD (3) · Brigitte C. Widemann, MD (2) · Brigitte Widemann, MD (2) · Chie-Schin Shih, MD (2) · D. Bradley Welling, MD, PhD (2) · Fu Zhao (2) · Pinan Liu (2) · William Tap, MD (2) · Zhiquan Huang, doctoral (2) · Aaron R Weiss (1)
PMID 28029918, PMID 32187457, PMID 15683544, PMID 17105749, PMID 21996156, PMID 22353803, PMID 26851632, PMID 28230061, PMID 28409229, PMID 31010905, PMID 31582003, PMID 33354735, PMID 33863389, PMID 34541874, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17336054, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20471824, PMID 23099009, PMID 23382028, PMID 24215845, PMID 24500418, PMID 24753394, PMID 26976425, PMID 27502708, PMID 27510726, PMID 27956565, PMID 29718344, PMID 30284154, PMID 30339775, PMID 30410720, PMID 31151904, PMID 31401903, PMID 31881853, PMID 31969335, PMID 32089640, PMID 32562630, PMID 32702309, PMID 32827353, PMID 33362722
U10CA180886 (4), P30CA008748 (3), N01CM62206 (2), U10CA098543 (2), U10CA180821 (2), 2009 (1), 2016 (1), 2017 (1), 2018 (1), N01CM17104 (1), N01CM62201 (1), N01CM62205 (1), P30CA006973 (1), P30CA012197 (1), P30CA013148 (1)